The British National Formulary is the unrivalled guidance on prescribing, dispensing and administering medicines.

The BNF is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors.

Sales and UpgradesContent Updates
Features and Benefits icon

Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients

Features and Benefits icon

Evidence Grading: As part of NICE accreditation recommendations, BNF content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making

Features and Benefits icon

Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you have access to the very latest prescribing knowledge

Features and Benefits icon

Worldwide credibility: The BNF uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely

1,500 +

drugs

290,000 +

users per month

200 +

treatment summaries

45million +

page views

Publication Updates

10 Jan
British National Formulary logo
British National Formulary January 2023 Update

This update contains 4 significant changes, 3 dose changes, 4 new monographs and 2 new preparations.

Significant Changes:
• Contraceptives, interactions: updated guidance.
• Depression: updated guidance on management.
• Hypertension: updated guidance for the management of patients with type 1 diabetes.
• Ozanimod (Zeposia®): new indication for ulcerative colitis.

Dose Changes:
Abilify Maintena® (aripiprazole) [addition of alternative initiation dosing].
Benlysta® (belimumab) [addition of subcutaneous dosing].
Cimzia® (certolizumab pegol) [update to dosing for ankylosing spondylitis].

New Monographs:
Drovelis® [drospirenone with estetrol].
Giapreza® [angiotensin II].
Hepcludex® [bulevirtide].
Welireg® [belzutifan].

New Preparations:
Efmody® [hydrocortisone]
Okedi® [risperidone].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

06 Dec
British National Formulary logo
British National Formulary December 2022 Update

This update contains 1 significant change, 4 dose changes, 4 new monographs and 2 new preparations.

Significant Change:
• Herpesvirus infections: updated guidance for post-exposure prophylaxis.

Dose Changes:
• Budesonide [update to dosing for intranasal administration for rhinitis and nasal polyps].
Jorveza® (budesonide) [update to dosing for eosinophilic oesophagitis].
• Lacosamide [update to age range for monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation].
• Melatonin [update to dosing for jet lag].

New Monographs:
Imcivree® [setmelanotide].
Kapruvia® [difelikefalin].
Oxbryta® [voxelotor].
Qinlock® [ripretinib].

New Preparations:
Actimorph® [morphine].
Dificlir® [fidaxomicin].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

08 Nov
British National Formulary logo
British National Formulary November 2022 Update

This update contains 5 significant changes, 1 dose change, 4 new monographs and 6 new preparations.

Significant Changes:
• COVID-19 vaccines: updated guidance for immunisation.
• Methylphenidate hydrochloride long-acting (modified-release) preparations: caution if switching between products due to differences in formulations [MHRA/CHM advice].
• Multiple sclerosis: updated guidance on management.
• Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists [MHRA/CHM advice] (advice in ipratropium bromide, salbutamol, terbutaline sulfate; see example in ipratropium bromide).
• Rucaparib (Rubraca®): withdrawal of third-line treatment indication [MHRA/CHM advice].

Dose Changes:
• Buprenorphine [update to indications and dose for transdermal patches].

New Monographs:
Sibnayal® [potassium citrate with potassium bicarbonate].
Tavneos® [avacopan].
Vydura® [rimegepant].
Vyepti® [eptinezumab].

New Preparations: Aloflute®, Avenor®, Seffalair Spiromax®, Sereflo Ciphaler®, Stalpex® [fluticasone with salmeterol]; Nuvaxovid® [COVID-19 vaccine].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

11 Oct
British National Formulary logo
British National Formulary October 2022 Update

This update contains 7 significant changes, 4 dose changes, 2 new monographs, and 2 new preparations.

Significant changes:
• Antibacterials, use for prophylaxis: updated guidance for the prevention of secondary cases of diphtheria, and addition of guidance for the prevention of intra-uterine infection in preterm prelabour rupture of membranes.
• Daratumumab (Darzalex®): updated pregnancy advice.
• Diphtheria vaccine: updated guidance for immunisation.
• Gout: updated guidance on management.
• Influenza vaccine: updated guidance for immunisation.
• Obstetrics: updated guidance for preterm labour.
• Valaciclovir [update to indication and doses in line with UK Health Security Agency recommendations on post-exposure prophylaxis for chickenpox and shingles].

Dose changes:
• Aciclovir [update to indication and doses in line with UK Health Security Agency recommendations on post-exposure prophylaxis for chickenpox and shingles].
• Colecalciferol [update to dosing for primary prevention and treatment of Vitamin D deficiency].
• Ergocalciferol [update to dosing for primary prevention and treatment of Vitamin D deficiency].
• Procyclidine hydrochloride [update to dosing for parkinsonism and drug-induced extrapyramidal symptoms].

New monographs:
Kimmtrak® [tebentafusp].
Scemblix® [asciminib].

New preparations:
Trimbow 172/5/9® [beclometasone with formoterol and glycopyrronium].
WockAIR® [budesonide with formoterol].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

13 Sep
British National Formulary logo
British National Formulary September 2022 Update

This update contains 9 significant changes, 6 new monographs, and 1 deleted preparation.

Significant Changes:
• Controlled drugs and drug dependence: updated guidance on the prescribing of drugs associated with dependence and withdrawal.
• Cystic fibrosis transmembrane conductance regulator modulators: update to hepatic impairment advice (see example in ivacaftor).
• Dexmedetomidine: clinical trial finds increased risk of mortality in intensive care unit (ICU) patients aged 65 years or younger [MHRA/CHM advice].
• Epilepsy: updated guidance on management.
• Hydrocortisone: addition of children’s dosing for adrenal crisis.
• Immunisation schedule: updated guidance for immunisation against influenza.
• Influenza vaccine: updated guidance for immunisation.
• Tezacaftor with ivacaftor and elexacaftor: name change to ivacaftor with tezacaftor and elexacaftor.
• Topiramate (Topamax®): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure [MHRA/CHM advice].

New Monographs:
Aklief® [trifarotene].
Brukinsa® [zanubrutinib].
• Magnesium citrate.
NovoThirteen® [factor XIII A-subunit (recombinant)].
Padcev® [enfortumab vedotin].
Palforzia® [peanut protein].

Deleted Preparation:
• Codeine phosphate solution for injection.

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

09 Aug
British National Formulary logo
British National Formulary August 2022 Update

This update contains 4 significant changes, 3 dose changes, 5 new monographs and 2 new preparations.

Significant Changes:
• Meropenem with vaborbactam [update to how dose is expressed].
• Metformin hydrochloride: reduced vitamin B12 levels and new advice for monitoring patients at risk [MHRA/CHM advice].
• Type 1 diabetes: inclusion of continuous glucose monitoring in aims of treatment.
• Type 2 diabetes: updated guidance for the use of non-insulin antidiabetic drugs.

Dose Changes:
• Cyanocobalamin [update to indications and dose].
• Empagliflozin [update to indication and dose (age ranges and heart failure indication amended), and advice on use and dosing in renal impairment].
• Sotrovimab [update to indications and dose to remove body-weight from dose statement].

New Monographs:
Bylvay® [odevixibat].
Ducressa® [dexamethasone with levofloxacin].
Gavreto® [pralsetinib].
Vabysmo® [faricimab].
Xerava® [eravacycline].

New Preparations: Orobalin® [cyanocobalamin]; Uxil® [dasatinib].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

View more View all content updates